Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during sytemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions

Brain Research

Volumn 765, Issue 2, 1997, Pages 183-188

  Smith, Trisha S ^a   Bennett Jr , James P ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Alzheimer's disease; Azide; Brain dialysis; Methylpyridinium; Nitric Oxide synthase Parkinson's disease; NMDA channel; Oxygen free radical

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AZIDE; DIZOCILPINE; HYDROXIDE; HYDROXYL RADICAL; MITOCHONDRIAL DNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYLPYRIDINIUM; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; PYRIDINIUM DERIVATIVE; REACTIVE OXYGEN METABOLITE; SCAVENGER; SODIUM AZIDE; TOXIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DEGENERATIVE DISEASE; MALE; MICRODIALYSIS; MITOCHONDRION; MODEL; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; AZIDES; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; HYDROXYL RADICAL; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; PYRIDINIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030882784     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00429-0     Document Type: Article

References (49)

1. R.H. Haas, F. Nasirian, D. Ward, K. Nakano, P. Ward, M. Pay, R. Hill, C.W. Schults, Low platelet mitochondrial complex I and complex II/III activity in early untreated early Parkinson disease, Ann. Neurol. 37 (1995) 714-722.
2. D. Krige, M.T. Carroll, J.M. Cooper, C.D. Marsden, A.H.V. Schapira, Platelet mitochondrial function in Parkinson's disease, Ann. Neurol. 32 (1992) 782-788.
3. W.D. Parker, S.J. Boyson, J.K. Parks, Abnormalities in the electron transport chain in idiopathic Parkinson's disease, Ann. Neurol. 26 (1989) 719-723.
4. C. Mytilineou, P. Werner, S. Molinari, A. Di Rocco, G. Cohen, M.D. Yahr, Impaired ixidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson' s disease, J. Neural Transm. 8 (1994) 223-228.
5. L.A. Bindhoff, M.A. Birch-Machen, N.E.F. Cartlidge, W.D. Parker, D.M. Turnbull, Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease, J. Neurol. Sci. 104 (1991) 203-208.
6. F. Cardellach, M.J. Marti, J. Fernandez-Sola et al., Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease, Neurology 43 (1993) 2258-2262.
7. A.H.V. Schapira, J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark, C.D. Marsden, Mitochondrial complex I deficiency in Parkinson's disease, Lancet i (1989) 1269.
8. A.H.V. Schapira, J.M. Cooper, D. Dexter, J.B. Clark, P. Jenner, C.D. Marsden, Mitochondrial complex I deficiency in Parkinson's disease, J. Neurochem. 54 (1990) 823-827.
9. A.H.V. Schapira, V.M. Mann, J.M. Cooper et al., Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease, J. Neurochem. 55 (1990) 2142-2145.
10. Y. Mizuno, S. Ikebe, N. Hattori, Y. Nakagawa-Hattori, H. Mochizuki, M. Tanaka, T. Ozawa, Role of mitochondria in the etiology and pathogenesis of Parkinson's disease, Biochim. Biophys. Acta 1271 (1995) 265-274.
11. W.D. Parker, C.M. Filley, J.K. Parks, Cytochrome oxidase deficiency in Alzheimer's disease, Neurology 40 (1990) 1302-1303.
12. S.J. Kish, C. Bergeron, A. Rajput et al., Brain cytochrome oxidase in Alzheimer's disease, J. Neurochem. 59 (1992) 776-779.
13. W.D. Parker, J.K. Parks, B.K. DeMasters, C.M. Filley, Electron transport chain defects in Alzheimer's disease brain, Neurology 44 (1994) 1090-1096.
14. W.D. Parker, N.J. Mahr, D. Hughes, C.M. Filley, C.M. Cullum, Reduced platelet cytochrome oxidase activity in Alzheimer's disease, Neurology 44 (1994) 1086-1090.
15. H.M. Schipper, S. Cisse, E.G. Stopa, Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain, Ann. Neurol. 37 (1995) 758-768.
16. N.A. Simonian, B.T. Hyman, Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation, J. Neuropathol. Exp. Neurol. 52 (1993) 580-584.
17. R.R. Ramsay, J. Dadgar, A. Trevor, T.P. Singer, Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP, Life Sci. 39 (1986) 581-588.
18. W.J. Nicklas, S.K. Youngster, M.V. Kindt, R.E. Heikkila, MPTP, MPP+ and mitochondrial function, Life Sci. 40 (1987) 721-729.
19. Y. Mizuno, K. Suzuki, N. Sone, T. Saitoh, Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo, Neurosci. Lett. 91 (1988) 349-353.
20. M. Gerlach, P. Riederer, H. Przuntek, M.B. Youdim, MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease, Eur. J. Pharmacol. 208 (1991) 273-286.
21. R.H. Swerdlow, J.P. Parks, S.M. Miller, J.B. Tuttle, P.A. Trimmer, J.P. Sheehan, J.P. Bennett Jr., R.E. Davis, W.D. Parker Jr., Origin of the complex I deficit in Parkinson's disease, Ann. Neurol. 40 (1996) 663-671.
22. J. Sheehan, R. Swerdlow, W. Parker, S. Miller, R. Davis, J. Tuttle, Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease, J. Neurochem. (1997, in press).
23. J. Sheehan, R. Swerdlow, S. Miller, W. Parker, R. Davis, J. Tuttle, Calcium homeostasis disturbances in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease (1997, in preparation).
24. T. Obata, C.C. Chiueh, In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP+ , and MPP+ , J. Neural Transm. 89 (1992) 139-145.
25. T.S. Smith, R.H. Swerdlow, W.D. Parker Jr., J.P. Bennett Jr., Reduction of MPP+-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase, NeuroReport 5 (1994) 2598-2600.
26. J.S. Beckman, T.W. Beckman, J. Chen, P.A. Marshall, B.A. Freeman, Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide, Proc. Natl. Acad. Sci. USA 87 (1990) 1620-1624.
27. R.S. Partridge, S.M. Monroe, J.K. Parks, K. Johnson, W.D. Parker Jr., G.R. Eaton, S.S. Eaton, Spin trapping of azidyl and hydroxyl radicals in azide-inhibited submitochondrial particles, Arch. Biochem. Biophys. 310 (1994) 210-217.
28. M.C. Bennett, D.M. Diamond, S.L. Stryker, J.K. Parks, W.D. Parker, Cytochrome oxdiase inhibition: a novel animal model of Alzheimer's disesease, J. Geriatr. Psychiatr. Neurol. 5 (1992) 93-101.
29. M.C. Bennett, G.W. Mlady, M. Fleshner, G.M. Rose, Synergy between chronic corticosterone and sodium azide treatments in producing a spatial learning deficit and inhibiting cytochrome oxidase activity, Proc. Natl. Acad. Sci. USA 93 (1996) 1330-1334.
30. L.-Y. Zang, H.P. Misra, Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, J. Cell Biol. 286 (1993) 16504-16512.
31. S. Kitayama, J.-B. Wang, G.R. Uhl, Dopamine transporter mutants selectively enhance MPP+ transport, Synapse 15 (1993) 58-62.
32. C. Pifl, B. Giros, M.G. Caron, Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium, J. Neurosci. 13 (1993) 4246-4253.
33. M. Herkenham, M.D. Little, K. Bankewicz, S.-C. Yang, S.P. Markey, J.N. Johannessen, Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study, Neuroscience 40 (1991) 133-158.
34. J.A. Javich, R.J. D'Amato, S.M. Strittmatter, S.H. Snyder, Parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite 1-methyl-4-phenyl-pyridinium by dopamine neurons explains selective toxicity, Proc. Natl. Acad. Sci. USA 82 (1985) 2173-2177.
35. R.A. Mayer, M.V. Kindt, R.E. Heikkila, Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylalanine transport, J. Neurochem. 47 (1986) 1073-1079.
36. S. Przedborski, V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, T.M. Dawson, Role of nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, Proc. Natl. Acad. Sci. USA 93 (1996) 4565-4571.
37. J.B. Schulz, R.T. Matthews, M.M.K. Muqit, S.E. Browne, M.F. Beal, Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice, J. Neurochem. 64 (1995) 936-939.
38. T. Hasegawa, K. Takeshige, T. Oishi, Y. Murai, S. Minakami, 1-Methyl-4-pyridinium (MPP+) induces NDAH-dependentsuperoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles, Biochem. Biophys. Res. Commun. 170 (1990) 1049-1055.
39. S. Przedborski, V. Kostic, V. Jackson-Lewis, A.B. Naini, S. Simonetti, S. Fahn, E. Carlson, C.J. Epstein, J.L. Cadet, Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity, J. Neurosci. 12 (1992) 1658-1667.
40. W.A. Pryor, G.L. Squadrito, The chemstry of peroxynitrite: a product from the reaction of nitric oxide with superoxide, Am. J. Physiol. 268 (1995) L699-L722.
41. J.P. Bolanos, S. Peuchen, S.J.R. Heales, J.M. Land, J.B. Clark, Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes, J. Neurochem. 63 (1994) 910-916.
42. J.P. Bolanos, S.J.R. Heales, J.M. Land, J.B. Clark, Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture, J. Neurochem. 64 (1995) 1965-1972.
43. S. Carboni, F. Melis, L. Pani, M. Hadjiconstantinou, Z.L. Rossetti, The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenypyridinium (MPP+), Neurosci. Lett. 117 (1990) 129-133.
44. A. Kupsch, P.-A. Loschmann, H. Sauer, G. Arnold, P. Renner, D. Pufal, M. Burg, H. Wachtel, G. Bruggencate, W.H. Oertel, Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice, Brain Res. 592 (1992) 74-83.
45. R. Srivastava, E. Brouillet, M.F. Beal, E. Storey, B.T. Hyman, Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss, Neurobiol. Aging 14 (1993) 295-301.
46. A. Tabatabaei, T.L. Perry, S. Hansen, C. Krieger, Partial protective effect of MK801 on MPTP-induced reduction of striatal dopamine in mice, Neurosci. Lett. 141 (1992) 192-194.
47. L. Turski, K. Bressler, K.-J. Rettig, P.-A. Loschmann, H. Wachtel, Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists, Nature 349 (1991) 414-418.
48. P. Hantraye, E. Brouillet, R. Ferrante, S. Palfi, R. Dolan, R.T. Matthews, M.F. Beal, Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons, Nature Med. 2 (1996) 1017-1021.
49. J.M. Shoffner, R.L. Watts, J.L. Juncos, A. Torroni, D.C. Wallace, Mitochondrial oxidative phosphorylation defects in Parkinson's disease, Ann. Neurol. 30 (1991) 332-339.